Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Investment analysts at Wedbush cut their FY2029 earnings per share (EPS) estimates for shares of Pharvaris in a report issued on Wednesday, August 13th. Wedbush analyst L. Chico now expects that the company will post earnings of $5.33 per share for the year, down from their prior estimate of $5.51. Wedbush currently has a "Outperform" rating and a $27.00 target price on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.
Other equities analysts also recently issued reports about the company. Guggenheim assumed coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price for the company. Cantor Fitzgerald decreased their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Finally, JMP Securities decreased their target price on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pharvaris presently has an average rating of "Buy" and an average price target of $35.60.
Check Out Our Latest Research Report on Pharvaris
Pharvaris Stock Performance
Shares of NASDAQ PHVS traded down $0.05 during trading on Thursday, reaching $21.38. The stock had a trading volume of 2,787 shares, compared to its average volume of 77,421. Pharvaris has a one year low of $11.51 and a one year high of $26.33. The stock has a market cap of $1.12 billion, a PE ratio of -6.36 and a beta of -2.81. The firm's 50 day moving average price is $19.46 and its two-hundred day moving average price is $17.17.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07).
Hedge Funds Weigh In On Pharvaris
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Soleus Capital Management L.P. boosted its position in shares of Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after buying an additional 216,483 shares during the period. Octagon Capital Advisors LP boosted its position in shares of Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after buying an additional 157,530 shares during the period. Rock Springs Capital Management LP boosted its position in shares of Pharvaris by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after buying an additional 18,200 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after buying an additional 118,408 shares during the period. Finally, TD Asset Management Inc boosted its position in shares of Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company's stock worth $1,751,000 after buying an additional 21,388 shares during the period.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access